米国の糖尿病性血管疾患治療装置市場：2007年

Abstract

In 2007, the US diabetic vascular disease treatment device market was valued at over $1 billion.

This market is comprised of devices for treating diabetic coronary revascularization, diabetic nephropathy, and diabetic neuropathy.

Table of Contents

TABLE OF CONTENTS

LIST OF EXHIBITS

EXECUTIVE SUMMARY

METHODOLOGY

1.0 US DIABETIC VASCULAR DISEASE TREATMENT DEVICE MARKET

• 1.1 Market Overview
• 1.2 Diabetes Mellitus
  • 1.2.1 Patient Population
  • 1.2.2 Diabetic Vascular Disease
  • 1.2.3 Macrovascular Complications of Diabetes
    • 1.2.3.1 Diabetic Coronary Artery Disease
  • 1.2.4 Microvascular Complications of Diabetes
    • 1.2.4.1 Diabetic Nephropathy
    • 1.2.4.2 Diabetic Neuropathy
    • 1.2.4.3 Diabetic Retinopathy
  • 1.2.5 Market Drivers & Limiters

2.0 DIABETIC CORONARY REVASCULARIZATION MARKET

• 2.1 Market Overview
  • 2.1.1 Diabetic Coronary Artery Disease
  • 2.1.2 Treatment Options
    • 2.1.2.1 Medical Management
    • 2.1.2.2 Coronary Revascularization
  • 2.1.3 PCI versus CABG in Patients with Diabetes
    • 2.1.3.1 Ongoing Clinical Trials
• 2.2 Market Analysis
  • 2.2.1 Coronary Revascularization Procedures
    • 2.2.1.1 PCI
    • 2.2.1.2 CABG Surgery
  • 2.2.2 Market Forecast
    • 2.2.2.1 Diabetic Coronary Stents
    • 2.2.2.2 PTCA Balloon Catheters
    • 2.2.2.3 Coronary Atherectomy Devices
  • 2.2.3 Market Drivers & Limiters
• 2.3 Competitive Analysis

3.0 DIABETIC NEPHROPATHY MARKET

• 3.1 Market Overview
• 3.2 Diabetic Nephropathy
  • 3.2.1 Diabetic ESRD
• 3.3 Market Analysis
  • 3.3.1 Arteriovenous Access Procedures
    • 3.3.1.1 Native AV Fistula
    • 3.3.1.2 Synthetic AV Graft
    • 3.3.1.3 Dialysis Catheter
  • 3.3.2 AV Access Management
    • 3.3.2.1 AV POBA Procedures
    • 3.3.2.2 AV Thrombectomy Procedures
  • 3.3.3 Market Forecast
    • 3.3.3.1 Dialysis Catheters in Diabetic Hemodialysis Patients
    • 3.3.3.2 Synthetic AV Grafts
    • 3.3.3.3 PTA Balloon Catheters for AV Access Management
    • 3.3.3.4 Thrombectomy Devices for AV Access Management
  • 3.3.4 Market Drivers & Limiters
• 3.4 Competitive Analysis

4.0 DIABETIC NEUROPATHY MARKET

• 4.1 Market Overview
• 4.2 Diabetic Neuropathy
• 4.3 Market Analysis
  • 4.3.1 Lower Extremity Revascularization Procedures
    • 4.3.1.1 PV Stent Procedures
    • 4.3.1.2 PTA Procedures
    • 4.3.1.3 Peripheral Atherectomy Procedures
    • 4.3.1.4 Lower Extremity Bypass Procedures
  • 4.3.2 Market Forecast
    • 4.3.2.1 PV Stents
    • 4.3.2.2 PTA Balloon Catheters
    • 4.3.2.3 Peripheral Atherectomy Devices
    • 4.3.2.4 Synthetic Bypass Graft Market
  • 4.3.3 Market Drivers & Limiters
• 4.4 Competitive Analysis

List of Exhibits

EXECUTIVE SUMMARY

• Exhibit 1: Diabetic Vascular Disease Treatment Device Market, US (US$), 2006-2012
• Exhibit 2: Diabetic Coronary Revascularization Procedures, as a % of Total, US, 2007 and 2012
• Exhibit 3: Diabetic Nephropathy Market, US (US$), 2006-2012
• Exhibit 4: Diabetic Neuropathy Market, as a % of Total, US, 2006-2012

METHODOLOGY

CHAPTER 1: US DIABETIC VASCULAR DISEASE TREATMENT DEVICE MARKET

• Exhibit 5: Diabetic Vascular Disease Treatment Device Market, US (US$), 2006-2012 (Graphical Format)
• Exhibit 6: Diabetic Vascular Disease Treatment Device Market, US (US$), 2006-2012 (Tabular Format)
• Exhibit 7: Total Prevalent and Diagnosed Cases of Diabetes Mellitus, by Type, US, 2006-2012
• Exhibit 8: Prevalent and Diagnosed Cases of Diabetic Nephropathy, Neuropathy, and Retinopathy, US, 2006-2012
• Exhibit 9: Drivers of the Diabetic Vascular Disease Treatment Device Market, US, 2007
• Exhibit 10: Limiters of the Diabetic Vascular Disease Treatment Device Market, US, 2007

CHAPTER 2: DIABETIC CORONARY REVASCULARIZATION MARKET

• Exhibit 11: Diabetic Coronary Revascularization Market, US (US$), 2006-2012 (Graphical Format)
• Exhibit 12: Diabetic Coronary Revascularization Market, US (US$), 2006-2012 (Tabular Format)
• Exhibit 13: Ongoing Clinical Trials in Diabetic Coronary Revascularization
• Exhibit 14: Treatment Algorithm for Patients with Diabetic Coronary Artery Disease, US, 2007
• Exhibit 15: Total Coronary Revascularization Procedures, by Type, US, 2006-2012
• Exhibit 16: Diabetic Penetration in Coronary Revascularization Procedures, by Segment, US, 2006-2012
• Exhibit 17: Diabetic Coronary Revascularization Procedures, by Type, US, 2006-2012
• Exhibit 18: Diabetic PCI Procedures, by Type, as a % of Total, US, 2006-2012
• Exhibit 19: Diabetic Stent Procedures, by Type, US, 2006-2012
• Exhibit 20: Diabetic Stent Procedures, by Device Type, US, 2006-2012
• Exhibit 21: Diabetic PTCA Balloon Procedures, by Type, 2006-2012
• Exhibit 22: Diabetic Coronary Atherectomy Procedures, by Subsequent PCI Treatment, US, 2006-2012
• Exhibit 23: Diabetic CABG Procedures, by Type, 2006-2012
• Exhibit 24: Diabetic Stent Market, by Device Type, US (US$), 2006-2012 (Tabular Format)
• Exhibit 25: Diabetic Stent Market Growth, by Device Type, US, 2007-2012
• Exhibit 26: Diabetic Stent Market, US (US$), 2006-2012 (Graphical Format)
• Exhibit 27: Diabetic Coronary Stents, by Type, US, 2006-2012
• Exhibit 28: Diabetic PTCA Balloon Catheter Market, US (US$), 2006-2012
• Exhibit 29: Diabetic PTCA Balloon Catheter Market, US, 2006-2012
• Exhibit 30: Diabetic Coronary Atherectomy Market, US (US$), 2006-2012 (Graphical Format)
• Exhibit 31: Coronary Atherectomy Market, US (US$), 2006-2012 (Tabular Format)
• Exhibit 32: Drivers of the Diabetic Coronary Revascularization Market, US
• Exhibit 33: Limiters of the Diabetic Coronary Revascularization Market, US
• Exhibit 34: Leading Competitors in the Coronary Revascularization Market, US, 2007 (Tabular Format)

CHAPTER 3: DIABETIC NEPHROPATHY

• Exhibit 38: Diabetic Nephropathy Market, US, 2006-2012
• Exhibit 39: Diabetic Nephropathy Market, US (US$), 2006-2012 (Tabular Format)
• Exhibit 35: Prevalent Cases of Diabetic Nephropathy, US, 2006-2012
• Exhibit 36: Prevalent Cases of Diabetic Nephropathy, by Severity, US, 2006-2012
• Exhibit 37: Prevalence and Incidence of ESRD and Diabetic ESRD, US, 2006-2012
• Exhibit 40: Prevalent Diabetic ESRD Population on Hemodialysis, by Mode of AV Access, US, 2006-2012
• Exhibit 41: Incident ESRD and Diabetic ESRD, by Initial Treatment Modality, US, 2006-2012
• Exhibit 42: Incident Diabetic ESRD Patients on Hemodialysis, by Mode of AV Access, as a % of Total US, 2006-2012
• Exhibit 43: Incident Diabetic Hemodialysis Patients with DC for Vascular Access, by DC Type, US, 2006-2012
• Exhibit 44: Treatment Algorithm for Incident Diabetic ESRD, US, 2007
• Exhibit 45: Treatment Algorithm for Prevalent Diabetic ESRD, US, 2007
• Exhibit 46: AV Access Management Procedures, US, 2006-2012
• Exhibit 47: AV POBA Procedures in Diabetic Patients, by Type of AV Access, US, 2006-2012
• Exhibit 48: DC Units in Incident Diabetic Patients, by DC Type, US, 2006-2012
• Exhibit 49: DC Units in Net Surviving Diabetic Patients from Previous Year, US, 2006-2012
• Exhibit 50: DC Units in Graft/Fistula Revision Procedures, by Type of AV Access, US, 2006-2012
• Exhibit 51: DC Units in Prevalent Diabetic Hemodialysis Patients, by DC Type, US, 2006-2012
• Exhibit 52: Diabetic Dialysis Catheter Market, US, 2006-2012 (Graphical Format)
• Exhibit 53: Diabetic Dialysis Catheter Market, by Type, As a % of Total US, 2006-2012
• Exhibit 54: Diabetic Dialysis Catheter Market Growth, by Type, US, 2007-2012
• Exhibit 55: Diabetic Synthetic AV Graft Market, US (US$), 2006-2012 (Graphical Format)
• Exhibit 56: Diabetic Synthetic AV Graft Market, US (US$), 2006-2012 (Tabular Format)
• Exhibit 57: Diabetic Arteriovenous PTA Balloon Catheter Market, US, 2006-2012 (Graphical Format)
• Exhibit 58: Diabetic Arteriovenous PTA Balloon Catheter Market, US, 2006-2012 (Tabular Format)
• Exhibit 59: Diabetic AV Thrombectomy Market, US (US$), 2006-2012 (Graphical Format)
• Exhibit 60: Diabetic AV Thrombectomy Market, US (US$), 2006-2012 (Tabular Format)
• Exhibit 61: Drivers of the Diabetic Nephropathy Market, US, 2007
• Exhibit 62: Limiters of the Diabetic Nephropathy Market, US, 2007
• Exhibit 63: Leading Competitors in the Diabetic Nephropathy Market, US, 2007

CHAPTER 4: DIABETIC NEUROPATHY

• Exhibit 64: Diabetic Neuropathy Market, US, 2006-2012 (Graphical Format)
• Exhibit 65: Diabetic Neuropathy Market, US, 2006-2012 (Tabular Format)
• Exhibit 66: Treatment Algorithm for Incident Cases of Diabetic Lower Extremity Vascular Disease, US, 2007
• Exhibit 67: Diabetic ATK Revascularization Procedures, by Device Type, US, 2006-2012
• Exhibit 68: Diabetic BTK Revascularization Procedures, by Device Type, US, 2006-2012
• Exhibit 69: Total Diabetic Lower Extremity Revascularization Procedures, by Device Type, US, 2006-2012 (Tabular Format)
• Exhibit 70: Total Diabetic Lower Extremity Revascularization Procedures, by Device Type, US, 2006-2012 (Graphical Format)
• Exhibit 71: Lower Extremity Revascularization Procedures, as a % of Total, US, 2006-2012
• Exhibit 72: Diabetic PV Stent Market, US (US$), 2006-2012 (Graphical Format)
• Exhibit 73: Diabetic PV Stent Market, by Indication, US, 2006-2012 (Tabular Format)
• Exhibit 74: Diabetic PV Stent Market Growth, by Indication US, 2006-2012
• Exhibit 75: Diabetic PTA Balloon Catheter Market, US (US$), 2006-2012 (Graphical Format)
• Exhibit 76: Diabetic PTA Balloon Catheter Market, US (US$), 2006-2012 (Tabular Format)
• Exhibit 77: Diabetic Peripheral Atherectomy Device Market, US (US$), 2006-2012 (Graphical Format)
• Exhibit 78: Diabetic Peripheral Atherectomy Device Market, US (US$), 2006-2012 (Tabular Format)
• Exhibit 79: Diabetic Synthetic Bypass Graft Market, US (US$), 2006-2012 (Graphical Format)
• Exhibit 80: Diabetic Synthetic Bypass Grafts Market, by Indication, US (US$), 2006-2012 (Tabular Format)
• Exhibit 81: Drivers of the Diabetic Neuropathy Market, US, 2007
• Exhibit 82: Limiters of the Diabetic Neuropathy Market, US
• Exhibit 83: Leading Competitors in the Diabetic Neuropathy Market, US, 2007